Research Progress of FLT3 Mutation in Acute Myeloid Leukemia --Review / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 922-926, 2023.
Artigo
em Chinês
| WPRIM
| ID: wpr-982152
ABSTRACT
Acute myeloid leukemia (AML) is a heterogeneous hematopoietic tumor originated from hematopoietic stem cells. FLT3 is an important receptor tyrosine kinase in cell signal transduction pathway and one of the common mutated genes in AML. AML patients with FLT3-ITD mutation have a poor prognosis and tendency to relapse. Therefore, early identification of FLT3 gene mutation and selection of appropriate treatment are particularly important. Currently, the small moleculetargeted drugs have been new treatment methods for AML patients with FLT3-ITD mutation, but accompanied drug resistance need to be solved. This paper reviews the mechanism of FLT3 mutation, the clinical significance of FLT3 mutation in AML, FLT3 inhibitors and drug resistance mechanism.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Leucemia Mieloide Aguda
/
Transdução de Sinais
/
Receptores Proteína Tirosina Quinases
/
Inibidores de Proteínas Quinases
/
Tirosina Quinase 3 Semelhante a fms
/
Mutação
Limite:
Humanos
Idioma:
Chinês
Revista:
Journal of Experimental Hematology
Ano de publicação:
2023
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS